• 1. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 2. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 3. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 4. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 5. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines Piperazine carboxylic acids and derivatives

Introduction to (R)-tert-Butyl 3-(hydroxymethyl)piperazine-1-carboxylate hydrochloride (CAS No. 1217444-84-2)

(R)-tert-Butyl 3-(hydroxymethyl)piperazine-1-carboxylate hydrochloride, identified by its CAS number 1217444-84-2, is a specialized chemical compound that has garnered significant attention in the field of pharmaceutical research and development. This compound belongs to the piperazine class of molecules, which are widely recognized for their diverse biological activities and potential therapeutic applications. The unique structural features of this compound, particularly its chiral center and the presence of both hydroxymethyl and carboxylate functional groups, make it a promising candidate for further investigation in drug discovery.

The< strong> (R)-configuration of the piperazine ring is crucial as it influences the stereochemical properties and biological interactions of the molecule. In recent years, there has been a growing interest in chiral drugs due to their improved efficacy and reduced side effects compared to their racemic counterparts. The< strong> tert-butyl group appended to the piperazine ring not only enhances the lipophilicity of the molecule but also contributes to its stability and solubility, making it more suitable for formulation into pharmaceutical products.

The< strong> hydroxymethyl group at the third position of the piperazine ring introduces a potential site for further chemical modification, enabling the synthesis of derivatives with enhanced pharmacological properties. This flexibility makes< strong> (R)-tert-butyl 3-(hydroxymethyl)piperazine-1-carboxylate hydrochloride a valuable scaffold for medicinal chemists seeking to develop novel therapeutic agents.

In recent studies, this compound has been explored for its potential role in modulating neurotransmitter systems, particularly those involving dopamine and serotonin. The piperazine moiety is known to interact with various receptors and enzymes in the central nervous system, making it a key component in the development of drugs for neurological disorders. Preliminary research suggests that< strong> (R)-tert-butyl 3-(hydroxymethyl)piperazine-1-carboxylate hydrochloride may exhibit anxiolytic and antidepressant-like effects, although further studies are needed to confirm these findings.

The< strong> carboxylate hydrochloride salt form of this compound enhances its solubility in aqueous solutions, which is essential for oral administration and parenteral delivery. This formulation improves bioavailability and facilitates controlled release, making it a more effective candidate for clinical use. The stability of the carboxylate group also ensures that the compound remains active during storage and transportation, maintaining its therapeutic integrity.

Advances in computational chemistry and molecular modeling have enabled researchers to predict the binding affinity and interaction patterns of< strong> (R)-tert-butyl 3-(hydroxymethyl)piperazine-1-carboxylate hydrochloride with biological targets. These simulations have provided valuable insights into its mechanism of action and have guided the design of more potent derivatives. Additionally, high-throughput screening techniques have been employed to identify new applications for this compound in various therapeutic areas.

The synthesis of< strong> (R)-tert-butyl 3-(hydroxymethyl)piperazine-1-carboxylate hydrochloride involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and enantiomeric purity. The use of chiral auxiliaries or catalysts is often necessary to achieve the desired stereochemical outcome. Recent innovations in asymmetric synthesis have made it possible to produce this compound more efficiently and cost-effectively, paving the way for large-scale production.

The pharmacokinetic properties of< strong> (R)-tert-butyl 3-(hydroxymethyl)piperazine-1-carboxylate hydrochloride have been thoroughly investigated to optimize its delivery and efficacy. Studies have shown that this compound exhibits moderate bioavailability following oral administration and has a relatively long half-life, allowing for once-daily dosing. These characteristics make it an attractive candidate for chronic treatment regimens.

In conclusion, (R)-tert-butyl 3-(hydroxymethyl)piperazine-1-carboxylate hydrochloride (CAS No. 1217444-84-2) is a versatile chemical entity with significant potential in pharmaceutical development. Its unique structural features, combined with its favorable pharmacokinetic properties, make it a promising candidate for further research into neurological disorders and other therapeutic applications. As our understanding of molecular interactions continues to evolve, compounds like this are likely to play a crucial role in shaping the future of drug discovery.

• 169448-87-7((R)-1-Boc-2-Hydroxymethyl-piperazine)
• 205434-75-9(Tert-butyl 2-(hydroxymethyl)piperazine-1-carboxylate)
• 301673-16-5(tert-butyl 3-(hydroxymethyl)piperazine-1-carboxylate)
• 143540-05-0(ditert-butyl 2-(hydroxymethyl)piperazine-1,4-dicarboxylate)
• 314741-40-7(tert-butyl (3S)-3-(hydroxymethyl)piperazine-1-carboxylate)
• 917572-36-2(1-Piperazinecarboxylic acid, 4-(3-azetidinyl)-3-(hydroxymethyl)-, 1,1-dimethylethyl ester)
• 911223-20-6(tert-butyl 3-(hydroxymethyl)-4-methylpiperazine-1-carboxylate)
• 278788-66-2(tert-butyl (3R)-3-(hydroxymethyl)piperazine-1-carboxylate)
• 1030377-21-9(tert-butyl (2S)-2-(hydroxymethyl)piperazine-1-carboxylate)
• 1203072-74-5(2-methyl-2-propanyl 3-(hydroxymethyl)-1-piperazinecarboxylate Hyd Rochloride (1:1))